Microarray Global Market Report 2024

The microarray market has grown strongly in recent years. It will grow from $4.73 billion in 2023 to $5.16 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The expansion witnessed in the historical period can be attributed to a surge in genomic research, an increase in the adoption of personalized medicine, advancements in pharmaceutical drug discovery, progress in cancer research, and the expansion of biotechnology and life sciences.

The microarray market is expected to see strong growth in the next few years. It will grow to $7.35 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be ascribed to the rapid expansion of molecular diagnostics, the emergence of precision medicine, heightened adoption in agriculture, the growth of microbiome research, and technological integration in healthcare. Significant trends expected in the forecast period encompass improvements in microarray data analysis tools, a focus on biomarker discovery for neurological disorders, increased utilization in infectious disease research, adoption in functional genomics studies, and expanding applications in drug discovery and development.

The future growth of the microarray market is anticipated to be driven by the increasing incidence of cancer cases. Cancer, characterized by uncontrolled cell growth and spread to other parts of the body, is on the rise due to factors such as established risk factors, exposure to specific chemicals, an aging population, and prevalent cancers such as breast cancer, lung cancer, and bronchial cancer. Microarray technology plays a crucial role in cancer research by enabling the identification of changes in gene expression associated with the disease. For example, the American Cancer Society estimates that around 9,910 children under the age of 15 will be diagnosed with cancer in the US in 2023, with approximately 1,040 children expected to succumb to the disease. Therefore, the increasing incidence of cancer cases is a key driver for the growth of the microarray market.

The growth of the microarray market is also expected to be propelled by the expanding pharmaceutical industry. This sector, involved in the discovery, development, and production of drugs and medicines, utilizes microarray technology for comprehensive analysis of gene expression, genetic variations, and molecular interactions. This facilitates advanced research in drug discovery, development, and personalized medicine. Reports from May 2021 by IQVIA Inc., a US-based pharmaceutical company, project that the total expenditure on pharmaceuticals in the US will range between $380 to $400 billion by 2025, reflecting a compound annual growth rate of 0-3% from $359 billion in 2020. Therefore, the growing pharmaceutical industry is a key factor driving the growth of the microarray market.

A noteworthy trend in the microarray market is the emphasis on product innovation by major market players. These companies are actively working on creating innovative products to strengthen their market position. For instance, in August 2023, Thermo Fisher Scientific, Inc., a US-based supplier of analytical instruments, life sciences solutions, and biotechnology services, launched the Applied Biosystems CytoScan HD Accel array. This chromosomal microarray is designed to enhance productivity, efficiency, and profitability in cytogenetic research labs, boasting an industry-leading two-day turnaround time. It offers comprehensive analysis of the entire human genome with enhanced coverage across 5,000 critical genomic regions, providing valuable insights into chromosomal variants for applications such as prenatal and postnatal research, as well as cancer-related studies.

Leading companies in the microarray market are focusing on the development of chromosomal microarrays to solidify their market position. Chromosomal Microarray Analysis (CMA) is considered a transformative technology in genomic medicine, significantly advancing diagnostic capabilities. For instance, in August 2023, Thermo Fisher Scientific Inc. introduced the Applied Biosystems CytoScan HD Accel array, contributing to improved productivity, efficiency, and profitability in cytogenetic research labs. This microarray facilitates comprehensive analysis of chromosomal variants for a broad range of research applications, including prenatal, postnatal, and oncology studies.

In September 2021, SCHOTT MINIFAB AG, a Germany-based manufacturer of microfluidic and microarray consumables, acquired Applied Microarrays (AMI) to enhance its position in microarray consumables and expand its biosensor printing capabilities. The acquisition is particularly significant in meeting the rising demand for point-of-care microarray consumables, especially in applications such as the detection of infectious diseases. Applied Microarrays, based in the US, specializes in manufacturing DNA and protein microarrays and biosensors.

Major companies operating in the microarray market report are Agilent Technologies Inc., Arrayit Corporation, Bio-Rad Laboratories Inc., Danaher Corporation, GE Healthcare Inc., Illumina Inc., Merck KGaA, Microarray Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., Molecular Devices LLC, BioMerieux Inc., RayBiotech Life Inc., Diasorin Group, NextGen Sciences Inc., PathogenDx Inc., Schott Minifab AG, Full Moon Biosystems Inc., CapitalBio Technology Co. Ltd., Roche Diagnostics, Biocare Medical, BioGenex Life Sciences Pvt. Ltd., BioGenomics Limited, BioMicro Systems Inc., Biostatus Limited, Biotechrabbit GmbH, Affymetrix Inc., F. Hoffmann-La Roche Ltd., SCIENION AG, INanoBio Inc.

North America was the largest region in the microarray market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global microarray market report during the forecast period. The regions covered in the microarray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of microarrays include DNA microarray, protein microarray, and others. A DNA microarray consists of small DNA spots affixed to a solid substrate, utilized to determine the presence of gene mutations, such as those in BRCA1 or BRCA2, within the DNA of a particular individual. This technology is employed across various domains, including disease diagnosis, cancer genomic analysis, drug discovery, genomic sequencing, expression analysis, and toxicological research. Its users span the pharmaceutical and biotechnology industries, academic and research laboratories, and other end-users.

The microarray market research report provides microarray market statistics, including the microarray industry’s global market size, regional shares, competitors with a microarray market share, detailed microarray market segments, market trends, and opportunities, and any further data you may need to thrive in the microarray industry. This microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The microarray market consists of revenues earned by entities by providing services such as genotyping and methylation array services, analytical protein microarray, functional protein array, reverse-phase protein array, and peptide microarray. The value of associated goods sold by the service provider or incorporated into the service providing is included in the market value. The microarray market also includes sales of microarray slides or chips and priming, microarray fluorescence and colorimetric scanners, printers, hybridization stations or DNA and RNA assays, whole genome sequencing, cDNA Microarray, BAC microarray, oligo microarray, which are used in providing microarray services. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.